


**SUPPLEMENTARY DATA****Table 1 of the supplementary data**

Description of TAVI procedure (n = 76)

<b>Procedure</b>	<b>n</b>	<b>%</b>
<i>Bicuspid, yes</i>	0	0.00
<i>Atrial flutter, yes</i>	22	28.90
<i>Valve-in-valve, yes</i>	6	7.90
<i>Vascular access</i>		
Right femoral	71	93.40
Left femoral	5	6.60
<i>Echo mode</i>		
Transoesophageal	1	1.30
Transthoracic	75	98.70
<i>Predilatation (no. of balloons before implantation)</i>		
0	70	92.10
1	4	5.30
2	1	1.30
3	1	1.30
<i>Closure</i>		
Angio-Seal	1	1.30
Surgical	4	5.30
ProGlide	71	93.40
<i>Anesthesia</i>		
General	1	1.30
Sedation	75	98.70


TAVI, transcatheter aortic valve implantation.

Figure 1 of the supplementary data. Death estimate in the overall sample



Estimated distributions from simulations of 1-year risk of death in the overall referral population (2018) matched by age and sex of patients included in the SARU study (STS PROM not included in the adjustment). Based on this, mortality rates seen in our study are similar to those from the overall population considering that the STS was not included in the adjustments (data from the National Statistics Institute, <https://www.ine.es/>).

**Figure 2 of the supplementary data** Echocardiographic outcomes at follow-up in the routine clinical practice



Post-op, postoperative; STS, Society of Thoracic Surgeons.